The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
28/04 8:24am 500k @ 23.5p = £117,500.00
Someone liked us - a lot ;)
Yep, looking like the right time to BUY.
Took a position this morning
Looks like Harry knew of placing when he called everyone a partner during his recent webcast.
Expect some envolved in placing have already forward sold into strength leaving some PIs holding placed shares @ 0.8p
No doubt he pumped the stock to satisfy the placing. Not nice.
Hope recent buyers were out on a high.
Early morning profit taking dumpers exhausted within 90 minutes.
Buyers taking price towards 60p
The journey continues.
nice story.
I assume he's too busy counting.
PP
Thanks for clarity. I thought it was 2.4p.
We need to double from here before warrants kick in @ 1.6p
Looking good for warrant holders, shareholders and company bank balance @ a 2.4p (or above) SP.
FY2022
I have guidance of 7.5million revenue for FY2022 - ending June 30th
Looking very good. Buy while it's low and wait.
If you like investing in pre-revenue mineral companies with potential high returns then KEFI has to be No.1 for choice.
No doubt, now is the 'time' to enter.
I can understand yrs of frustration for long term investors. But, as a new investment the timing couldn't be better.
Best of luck.
Thanks Folks.
Appreciated.
Nice paragraph that caught my eye:
KEFI has an estimated NPV of 12.9p/share, based on the attributable values of the three
projects, and a gold price of US$1,830/oz. A portfolio of six other companies with gold
development projects in Africa, and with similar gold price assumptions, currently trades at
43% of NPV. Valuing KEFI in line with peers would suggest a valuation of 5.5p/share. The
market is currently KEFI at just 6% of NPV. On this basis, KEFI is arguably one of the
most undervalued gold developers, anywhere.